HWHaitao Wang

Haitao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haitao Wang has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Lili Wang

    Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Reseach Center for Cancer, Tianjin, 300060, China

    7 shared publications
  • Bin Huo

    Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

    4 shared publications
  • Dingkun Hou

    Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Precision Medicine for Sex Hormones and Disease (in Preparation), Tianjin, 300211, China

    4 shared publications
  • Lei Wang

    Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

    4 shared publications
  • Xiaodong Huo

    Department of Oncology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

    4 shared publications
  • Guangjun Zheng

    Department of Thoracic Surgery, Second Hospital of Tianjin Medical University Tianjin 300211, China

    3 shared publications

Latest Publications

  • Open Access

    A nomogram integrating mutation signatures and clinical features for prognostic stratification in bladder cancer

    by Lili Wang, Peng Chen, Huanhuan Liu, Jiayue Qin, Shanbo Cao, Hongzheng Li, Dingkun Hou, Kaibin Wang, Haitao Wang

    Bladder cancer (BLCA) is a typical malignancy in the urinary tract, with a dismal survival rate and limited therapeutic options. There is a growing demand for clinically relevant biomarkers to effectively stratify prognosis. This study aims to develop a prognostic model utilizing mutation signatures and clinical characteristics to inform the clinical management of BLCA. The data of 631 BLCA patients were retrospectively reviewed, including 538 patients from The Cancer Genome Atlas (TCGA) and 93 patients from a Chinese cohort. Univariate and multivariate analyses were performed to identify the independent prognostic factors for overall survival (OS). Multivariate Cox regression analysis revealed that a 30-mutated gene signature and age were independent prognostic factors for BLCA. The prognostic nomogram was constructed to predict the probability of 1-, 3-, and 5-year OS, achieving area under the curve (AUC) values of 0.800, 0.749, and 0.731 in the training group, and 0.641, 0.820, and 0.759 in the validation group, respectively. Additionally, high risk scores were associated with poorer outcomes across all clinical subgroups. Patients with high-risk profiles exhibited higher neoantigen burden (p = 0.029), copy number variation (CNV) count (p = 0.013), and DNA damage response (DDR) mutations (p < 0.001) compared to those with low-risk profiles. The model incorporating mutation signatures and clinical factors demonstrated accuracy in predicting changing cancer survival risk over time.This suggests that the model has the potential to serve as a valuable prognostic tool for BLCA.


  • Open Access

    Spermidine restricts neonatal inflammation via metabolic shaping of polymorphonuclear myeloid-derived suppressor cells

    by Jiale Chen, Lin Zhu, Zhaohai Cui, Yuxin Zhang, Ran Jia, Dongmei Zhou, Bo Hu, Wei Zhong, Jin Xu, Lijuan Zhang, et al.

    Newborns exhibit a heightened vulnerability to inflammatory disorders due to their underdeveloped immune system, yet the underlying mechanisms remain poorly understood. Here we report that plasma spermidine is correlated with the maturity of human newborns and reduced risk of inflammation. Administration of spermidine led to the remission of neonatal inflammation in mice. Mechanistic studies revealed that spermidine enhanced the generation of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) via downstream eIF5A hypusination. Genetic deficiency or pharmacological inhibition of deoxyhypusine synthase (DHPS), a key enzyme of hypusinated eIF5A (eIF5A Hyp ), diminished the immunosuppressive activity of PMN-MDSCs, leading to aggravated neonatal inflammation. The eIF5A Hyp pathway was found to enhance the immunosuppressive function via histone acetylation–mediated epigenetic transcription of immunosuppressive signatures in PMN-MDSCs. These findings demonstrate the spermidine-eIF5A Hyp metabolic axis as a master switch to restrict neonatal inflammation.


  • Open Access

    NFYA-mediated promotion of castration-resistant prostate cancer progression through EGR4 regulation

    by Guijiang Sun, Yi Shao, Qianwang Ma, Shengju Song, Yutong Chen, Yang Li, Yue Gao, Haitao Wang, Zhiqun Shang

    This research investigates the intricate involvement of nuclear Transcription Factor Y Subunit Alpha (NFYA) in the advancement of castration-resistant prostate cancer (CRPC) and its consequential impact on early Growth Response 4 (EGR4) expression. NFYA demonstrates a significant elevation in CRPC tissues and cell lines, displaying robust upregulation in metastatic prostate cancer (mPCa) samples, closely associated with the Gleason score. Immunohistochemistry validates heightened nuclear staining of NFYA in CRPC patients, highlighting its crucial role in the progression of advanced prostate cancer. Silencing NFYA through siRNA in androgen-independent cell lines markedly impedes cell growth and migration, emphasizing NFYA’s pivotal role in promoting CRPC behavior. RNA-seq analysis identifies EGR4 as a downstream target of NFYA, with both genes consistently upregulated in CRPC. Validating this finding, heightened expression of EGR4 is observed in CRPC samples. In vivo studies utilizing a mouse model demonstrate that NFYA silencing substantially inhibits LNCaP-AI/22RV1shNFYA xenograft tumor growth, accompanied by reduced expression of EGR4 and Ki67. This comprehensive study reveals the multifaceted role of NFYA in CRPC progression, elucidates its downstream impact on EGR4, and underscores the therapeutic potential of targeting NFYA to inhibit CRPC growth in vivo. These findings contribute valuable insights into potential therapeutic strategies for managing CRPC.


  • Open Access

    Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer

    by Zhouliang Wu, Gangjian Zhao, Zhe Zhang, Chong Shen, Lili Wang, Guoping Xu, Yang Zhao, Rui Liang, Changping Li, Huanhuan Liu, et al.


  • Open Access

    Tumor-associated macrophages and PD-L1 in prostate cancer: a possible key to unlocking immunotherapy efficacy

    by Jinhuan Wang, Wenqi Wu, Tian Yuan, Lili Wang, Li Zang, Qing Liu, Lei Wang, Xiaodong Huo, Bin Huo, Yong Tang, et al.

    Purpose: Prostate cancer (PCa) is often considered as a “cold” tumor with low responsiveness to immunotherapy. Recent evidence suggests the activation of specific immune cells, such as tumor-associated macrophages (TAMs), could potentially influence the efficacy of immunotherapy in PCa. However, the relationship between TAMs and PD-L1, a significant regulator in immunotherapy, within PCa remains unexplored. Methods: In this study, we assessed TAM infiltration and PD-L1 expression levels in a local cohort of 95 PCa tissue samples and two publicly available PCa datasets. We employed a combination of bioinformatics and experimental techniques, including gene set enrichment analysis, CIBERSORTx, tissue microarray, immunohistochemistry staining, and analysis of single-cell sequencing datasets, to provide a comprehensive understanding of the association between PD-L1 and TAMs in the PCa microenvironment. Results: The study showed that CD68+ TAMs and CD163+ TAMs (M2-TAMs) were more abundant in the tumor microenvironment than in non-cancerous surrounding tissues. The infiltration of CD163+ TAMs was significantly associated with the Gleason score and risk stratification of PCa. Importantly, elevated PD-L1 expression correlated significantly with high infiltration of CD163+ TAMs. Furthermore, patients displaying high levels of CD163+ TAMs and PD-L1 expression exhibited shorter times to biochemical recurrence-free survival. Conclusion: Our study suggests that CD163+ TAMs are closely associated with PD-L1 expression and can act as a valuable prognostic indicator for PCa. The high infiltration of M2-TAMs, coupled with the overexpression of PD-L1, may contribute to immune escape mechanisms in PCa, thereby influencing disease prognosis.


  • DNA‐repair status should be assessed in treatment‐emergent neuroendocrine prostate cancer before platinum‐based therapy

    by Shimiao Zhu, Zheng Zhang, Hui Zhang, Zihao Liu, Min Liu, Qing Liu, Li Zang, Lili Wang, Junpeng Ji, Bo Wu, et al.

    Objectives: This study sought to provide contemporary data from a multi‐institution with respect to DNA‐repair genes (DRGs) status and its impact on effects of platinum‐based chemotherapy in treatment‐emergent neuroendocrine prostate cancer (t‐NEPC), for which little data exist.Patients and Methods: All patients were retrospectively collected with eligible biopsied tissues for targeted next generation sequencing (NGS). The main outcomes were radiologic progression‐free survival and overall survival according to Response Evaluation Criteria in Solid Tumors, version 1.1.Results: Among the 43 NEPC patients, 13/43 (30%) harbored homozygous deletions, deleterious mutations, or both in DRGs. Eleven patients (11/13, 85%) with DRGs aberrations had effective response, including 7 patients with BRCA1/2 defects and 2 with mismatch repair‐deficient caused by MSH2 alterations. While significantly fewer responders (30%) were detected in patients without DRGs aberrations (odds ratio = 12.83, p = 0.003). Compared with patients without genomic DRGs aberrations, the hazard ratio (HR) for radiologic progression in those with DRGs defects was 0.42 (95% confidence interval [CI]: 0.19–0.93), and the HR for death was 0.65 (95% CI: 0.24–1.72). The most common adverse event of Grade 3 or 4 was anemia, as noted in 7 patients (16%).Conclusion: The DRGs status is therapeutically meaningful in t‐NEPC. Given the potential responses to platinum‐based chemotherapy, our findings support the clinical use of NGS in t‐NEPC patients to identify DRGs aberrations.


  • Open Access

    Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients

    by Hong Zong, Jian Zhang, Zhengyang Xu, Jia-Ni Pan, Rong Wang, Jinming Han, Miao Jiang, Ruiping Ren, Li Zang, Haitao Wang, et al.

    Purpose: Mutations leading to homologous recombination deficiency (HRD) increase the tumor sensitivity to platinum-based chemotherapy and PARP inhibitors. However, reversion mutations often develop conferring acquired drug resistance. There is still a lack of comprehensive investigation on HRR reversion mutations in large pan-cancer cohorts, especially in the Eastern Asian population. This study aims to characterize reversion mutations in homologous recombination repair (HRR)-related genes in a large cohort of Chinese pan-cancer patients.


  • Open Access

    A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer

    by Lili Wang, Yun Peng, Shiqiang Dong, Dingkun Hou, Nan Li, Hongzheng Li, Tianyang Li, Zheyu Zhang, Haitao Wang

    A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer Lili Wang, Yun Peng, Shiqiang Dong, Dingkun Hou, Nan Li, Hongzheng Li, Tianyang Li, Zheyu Zhang, Haitao Wang


  • Open Access

    Benefits from standalone durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

    by Lili Wang, Lei Wang, Dingkun Hou, Shiqiang Dong, Aixiang Wang, Haitao Wang

    There is a lacking of effective therapeutic strategies in the treatment of advanced prostatic sarcoma with high-frequency microsatellite instability (MSI-H) or mismatch repair deficient (dMMR). In this study, we present the first described a case of advanced MSI-H and dMMR prostatic sarcoma in elderly patients with multiple comorbidities, who received an anti-PD-L1 monoclonal antibody (durvalumab) as the first-line treatment and achieved partial remission (PR) without visible adverse events. A 91-year-old male patient presented with frequent urination and defecation difficulty for over three months, aggravating for ten days. Digital rectal examination showed the prostate gland was III° enlargement and tough with a smooth surface. The MRI showed occupying lesions in the prostate without distant metastasis. Then, the prostate biopsy showed poorly differentiated small round cell malignant tumor and considered prostatic sarcoma. Immunohistochemistry showed MSI-H and dMMR prostatic sarcoma. Durvalumab alone was applied at a cycle of every 21 days (500 mg/day) for 18 months and achieved PR two months since the treatment. During the treatment, we didn’t observe rash, immune-related pneumonia, hepatitis, and other adverse events. Also, no recurrence or metastasis was observed until now. Durvalumab is effective and safe in the treatment of advanced MSI-H or dMMR prostatic sarcoma in an elderly patient. It is promising to be an available choice for advanced prostate sarcoma, which is unsuitable for surgery, conventional chemotherapy, and radiotherapy.


  • Top Cited Papers
    Open Access

    LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling

    by Yangyi Zhang, Shanqi Guo, Shuo Wang, Xiaojian Li, Dingkun Hou, Hongzheng Li, Lili Wang, Yong Xu, Baojie Ma, Haitao Wang, et al.